Jounce Therapeutics, Inc. (JNCE) Analysts See $-0.37 EPS; Cullen Capital Management Has Boosted Sk Telecom Company LTD (Adr) (SKM) Holding By $629,280

July 25, 2018 - By Victoria Pittman

SK Telecom Co., Ltd. (NYSE:SKM) Logo

Cullen Capital Management Llc increased Sk Telecom Company Ltd. (Adr) (SKM) stake by 193.29% reported in 2018Q1 SEC filing. Cullen Capital Management Llc acquired 26,220 shares as Sk Telecom Company Ltd. (Adr) (SKM)’s stock declined 5.58%. The Cullen Capital Management Llc holds 39,785 shares with $962,000 value, up from 13,565 last quarter. Sk Telecom Company Ltd. (Adr) now has $15.97B valuation. The stock decreased 0.04% or $0.01 during the last trading session, reaching $23.82. About 167,418 shares traded. SK Telecom Co., Ltd. (NYSE:SKM) has declined 6.15% since July 25, 2017 and is downtrending. It has underperformed by 18.72% the S&P500. Some Historical SKM News: 07/03/2018 REG-SK Telecom Co Ld: Submission of audit report – Non-consolidated; 09/04/2018 – REG-SK Telecom Co Ld: Explanation regarding Acquisition; 08/04/2018 – S&PGR Rates SK Telecom’s Proposed US$ Notes ‘A-‘; 04/05/2018 – REG-SK Telecom Co Ld: 2018 1Q Earnings Results; 07/05/2018 – S.KOREA’S SK TELECOM SAYS TO BUY 702 BLN WON WORTH STAKE IN OWNER OF SECURITY FIRM ADT CAPS; 27/04/2018 – SK Telecom Co. Ltd. Files Its Annual Report on Form 20-F; 03/05/2018 – SK TELECOM 1Q OPER PROFIT 325.5B WON, EST. 375.63B WON; 15/03/2018 – S.Korea’s SK Telecom says considering acquiring Carlyle’s ADT Caps; 09/04/2018 – Moody’s Assigns A3 To Sk Telecom’s Usd Notes; 10/05/2018 – Moody’s Cites SK Telecom’s Acquisition of ADT Caps

Analysts expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) to report $-0.37 EPS on August, 8.They anticipate $0.26 EPS change or 236.36% from last quarter’s $-0.11 EPS. After having $-0.40 EPS previously, Jounce Therapeutics, Inc.’s analysts see -7.50% EPS growth. The stock decreased 2.45% or $0.18 during the last trading session, reaching $7.18. About 175,114 shares traded. Jounce Therapeutics, Inc. (NASDAQ:JNCE) has declined 49.76% since July 25, 2017 and is downtrending. It has underperformed by 62.33% the S&P500. Some Historical JNCE News: 18/04/2018 – U.S. FDA Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Small Cell Lung Cancer and Grants Priority Review; 30/04/2018 – FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and; 08/03/2018 – Jounce Therapeutics 4Q Loss/Shr 29c; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell; 16/04/2018 – BRISTOL-MYERS SQUIBB – IN PHASE 3 CHECKMATE -214 TRIAL, OPDIVO + YERVOY ALSO DELIVERED DURABLE RESPONSES, WITH HIGHER OBJECTIVE RESPONSE RATE VS SUNITINIB; 16/04/2018 – IN CHECKMATE -141, OPDIVO (NIVOLUMAB) DEMONSTRATED SUSTAINED OVERALL SURVIVAL (OS) ADVANTAGE OVER STANDARD OF CARE IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND; 13/03/2018 – Merck Gets FDA Priority Review for Keytruda sBLA in Advanced Cervical Cancer; 08/03/2018 – JOUNCE THERAPEUTICS INC – EXPECTS TO RECORD APPROXIMATELY $50.0 MLN TO $60.0 MLN IN COLLABORATION REVENUE IN 2018; 07/03/2018 – MERCK & CO – CO, ISAI TO DEVELOP AND COMMERCIALIZE LENVIMA JOINTLY, BOTH AS MONOTHERAPY AND IN COMBINATION WITH MERCK’S ANTI-PD-1 THERAPY, KEYTRUDA; 09/04/2018 – KEYTRUDA MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3

More news for SK Telecom Co., Ltd. (NYSE:SKM) were recently published by:, which released: “Korea Telecom” on July 08, 2018.‘s article titled: “Korea Telecom: Senior Discount, The Last Puzzle To Phone Bill Cuts” and published on July 15, 2018 is yet another important article.

Cullen Capital Management Llc decreased Smurfit Kappa Group Plc (SMFTF) stake by 26,685 shares to 210,740 valued at $8.54 million in 2018Q1. It also reduced Roche Holding Ag (RHHVF) stake by 4,240 shares and now owns 14,405 shares. Ctci Corp. was reduced too.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $233.23 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: